VIRGINIA BEACH, Va. (WAVY) — One Ocean Lakes High School student made the semi-finals of the prestigious Regeneron Science ...

Regeneron Pharmaceuticals continues to show strong growth, driven by Dupixent's FDA approval for COPD and Eylea HD's market resilience against biosimilars. Q3 earnings beat expectations with $3.72 ...

Dec 16 - Regeneron Pharmaceuticals (REGN.O), opens new tab has settled allegations that it misused a patented protein to test its COVID-19 treatment REGEN-COV, according to filings in New York ...

Regeneron Pharmaceuticals (NASDAQ:REGN), the maker of eye disease therapy Eylea, has acquired Oxular, a U.K.-based biotech drug developer focused on ophthalmology. While neither company formally ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 10 trades.

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%. The stock has underperformed the sector and the S&P 500 Index ...

Financial giants have made a conspicuous bearish move on Regeneron Pharmaceuticals. Our analysis of options history for Regeneron Pharmaceuticals REGN revealed 10 unusual trades. Delving into the ...

Since its August 2023 launch, Eylea HD has started making significant contributions to Regeneron's top line. During this year's third quarter, the drug generated $392 million in U.S. sales.

Regeneron's EYLEA HD met the primary endpoint in the Phase 3 QUASAR trial for macular edema following retinal vein occlusion. Vision gains with EYLEA HD every 8 weeks matched the current standard ...

Attorney General Josh Stein, the Democratic candidate for governor, speaks during the North Carolina Democratic Party Unity Dinner at the Raleigh Convention Center Saturday, July 20, 2024.

Three of the region’s biggest manufacturers – Regeneron, Plug Power and GlobalFoundries – made big news in 2024 and next year could be similarly eventful. Below is a closer look at what 2025 ...

Regeneron Pharmaceuticals has announced positive Phase 2 results for two investigational monoclonal antibodies, REGN7508 and REGN9933, which target different domains of Factor XI to control ...